Eamonn Martin Quigley, MD

David M. Underwood Chair of Medicine in Digestive Disorders, Department of Medicine
Professor of Medicine, Institute for Academic Medicine
Director, Lynda K. and David M. Underwood Center for Digestive Disorders
Houston Methodist
Weill Cornell Medical College


Biography

Dr. Eamonn M. M. Quigley, past president of the American College of Gastroenterology and the World Gastroenterology Organization, joined the faculty at The Methodist Hospital as head of its Gastroenterology and Hepatology division in 2013.

Prior to his move to Houston, Quigley was professor of medicine and human physiology and a principal investigator at the Alimentary Pharmabiotic Centre at the National University of Ireland in Cork. He is internationally known for his research on gastrointestinal motility disorders, primarily irritable bowel syndrome (IBS); gastroesophageal reflux disease (GERD); neurogastroenterology (the relationship between the central nervous system and the gut); the gut microbiome and probiotics in health and disease. A highlight of his ongoing research includes how bacteria in the digestive tract play a major role in pulling nutrients from food to nourish the body, as well as participating in protecting the body from disease.

IBS is the most common, chronic medical condition in the United States. Approximately 40 percent of those with IBS have symptoms severe or frequent enough to disrupt their daily lives. While the cause of IBS has not been clearly identified, Quigley’s clinical research suggests that an alteration of the normal gut bacteria flora may be a cause. His research team is working toward developing new biomarkers for IBS which would eventually lead to the development of new treatments. Quigley’s clinical interests focus on the use of probiotics for the treatment of IBS.

Some of his pioneering research over the past several decades has included how the function of the gut is affected in a variety of diseases and conditions, including chronic liver disease, high-dose chemoradiotherapy, intestinal failure and transplantation, and Parkinson’s disease.

He has published more than 800 peer-reviewed articles, reviews, editorials, book chapters and case reports, mostly in the areas of gut motility, functional gastrointestinal disorders, and GERD. Quigley has received numerous international honors and awards. He served as Editor-in-Chief of the American Journal of Gastroenterology from 1997 to 2003.

Quigley received his medical degree from  University College Cork in Cork, Ireland; completed internal medicine residency in Glasgow, Scotland; and did GI fellowship training at the Mayo Clinic and the University of Manchester in England.  He served as the Chief of Gastroenterology at the University of Nebraska from 1991 to 1998 and as Dean of the Medical School in Cork, Ireland from 2000 to 2007.

Areas Of Expertise

Gastroesophageal Reflux Esophageal disorders/dysphagia Gastrointestinal motility disorders Functional GI disorders Irritable bowel syndrome Gastroparesis Constipation Diarrheal disorders Celiac disease Intestinal & colonic disorders Inflammatory bowel disease/colitis/Crohn's disease General gastroenterology EGD and colonoscopy Capsule endoscopy
Education & Training

, University of Manchester
, Western Infirmary & Associates Hospital
, St. Finbarr's Hospital
, National University of Ireland;
Publications

Leptin modifies the prosecretory and prokinetic effects of the inflammatory cytokine interleukin-6 on colonic function in Sprague–Dawley rats
Buckley, MM, OBrien, R, Devlin, M, Creed, AA, Rae, MG, Hyland, NP, Quigley, EMM, McKernan, DP & OMalley, D 2016, Experimental Physiology, vol 101, no. 12, pp. 1477-1491. DOI:

Editorial: balancing fibre and FODMAPs in IBS - a 'rye' look at an old problem
Quigley, EMM 2016, Alimentary Pharmacology and Therapeutics, vol 44, no. 10, pp. 1134-1135. DOI:

Editorial: balancing fibre and FODMAPs in IBS – a ‘rye’ look at an old problem
Quigley, EMM 2016, Alimentary Pharmacology and Therapeutics, vol 44, no. 10, pp. 1134-1135. DOI:

Colonic ischemia: usual and unusual presentations and their management
Oglat, A & Quigley, EMM 2016, Current Opinion in Gastroenterology. DOI:

Leptin modifies the pro-secretory and pro-kinetic effects of the inflammatory cytokine, interleukin-6 on colonic function in Sprague Dawley rats
Buckley, MM, OBrien, R, Devlin, M, Creed, AA, Rae, MG, Hyland, NP, Quigley, EMM, McKernan, DP & OMalley, D 2016, Experimental Physiology. DOI:

Progress in Our Understanding of the Gut Microbiome: Implications for the Clinician
Iqbal, S & Quigley, EMM 2016, Current Gastroenterology Reports, vol 18, no. 9, 49. DOI:

Immune response in irritable bowel syndrome: A systematic review of systemic and mucosal inflammatory mediators
Martin-Viñas, JJ & Quigley, EMM 2016, Journal of Digestive Diseases. DOI:

The intestinal microenvironment and functional gastrointestinal disorders
Barbara, G, Feinle-Bisset, C, Ghoshal, UC, Santos, J, Vanner, SJ, Vergnolle, N, Zoetendal, EG & Quigley, EM 2016, Gastroenterology, vol 150, no. 6, pp. 1305-1318e8. DOI:

Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials
Camilleri, M, Piessevaux, H, Yiannakou, Y, Tack, J, Kerstens, R, Quigley, EMM, Ke, MY, da Silva, S & Levine, A 2016, Digestive Diseases and Sciences, pp. 1-16. DOI:

Advancing treatment options for chronic idiopathic constipation
Quigley, EMM & Neshatian, L 2016, Expert Opinion on Pharmacotherapy, vol 17, no. 4, pp. 501-511. DOI:

Overlapping irritable bowel syndrome and inflammatory bowel disease: Less to this than meets the eye?
Quigley, EMM 2016, Therapeutic Advances in Gastroenterology, vol 9, no. 2, pp. 199-212. DOI:

Editorial introductions
Shanahan, F & Quigley, EMM 2016, Current Opinion in Gastroenterology, vol 32, no. 2, pp. v. DOI:

Leaky gut-concept or clinical entity?
Quigley, EMM 2016, Current Opinion in Gastroenterology, vol 32, no. 2, pp. 74-79. DOI:

Editorial: Serotonin and irritable bowel syndrome - Reconciling pharmacological effects with basic biology
Quigley, EMM 2016, Alimentary Pharmacology and Therapeutics, vol 43, no. 5, pp. 644-646. DOI:

Constipation and the Microbiome: Lumen Versus Mucosa!
Quigley, EMM & Spiller, RC 2016, Gastroenterology, vol 150, no. 2, pp. 300-303. DOI:

Features of patients with inflammatory bowel diseases who develop hemophagocytic lymphohistiocytosis
Li, Y, Li, CF, Zhang, J, Xia, XF, Zhou, LY, Liu, JJ, Song, ZQ, Lv, YM, Wang, AY, Zhang, YP, Liang, CF, Shi, YY, Quigley, EM, Huang, YH & Ding, SG 2016, International Journal of Colorectal Disease. DOI:

Probiotic nomenclature matters
Hill, C, Scott, K, Klaenhammer, TR, Quigley, E & Sanders, ME 2016, Gut Microbes, vol 7, no. 1, pp. 1-2. DOI:

Advances in colonic disease: Some light at the end of the tunnel at the end of the light!
Quigley, EMM 2016, Current Opinion in Gastroenterology, vol 32, no. 1. DOI:

World gastroenterology organisation global guidelines irritable bowel syndrome a global perspective update September 2015
Quigley, EMM, Fried, M, Gwee, KA, Khalif, I, Hungin, APS, Lindberg, G, Abbas, Z, Fernandez, LB, Bhatia, SJ, Schmulson, M, Olano, C & LeMair, A 2016, Journal of Clinical Gastroenterology, vol 50, no. 9, pp. 704-713. DOI:

Microbiota-gut-brain signalling in Parkinson's disease: Implications for non-motor symptoms
Felice, VD, Quigley, EM, Sullivan, AM, OKeeffe, GW & OMahony, SM 2015, Parkinsonism and Related Disorders. DOI: